E-LIB Suche - Ergebnisse für: Nachury, M.

1

P836 Prospective evaluation of the switch from adalimumab o..:

D'Abbundo, G ; Nachury, M ; Hambli, S...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1557-i1557 , 2024

2

P766 No difference in progression of disability 2 years aft..:

Vieujean, S ; Desseaux, K ; Laharie, D...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1429-i1431 , 2024

Link: https://doi.org/10.1093/..

3

DOP05 Bowel damage and its correlation with the disability ..:

Revés, J ; Roager Madsen, G ; Burisch, J...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i79-i80 , 2024

Link: https://doi.org/10.1093/..

4

P927 Long-term outcomes of risankizumab in Crohn's disease:..:

Fumery, M ; Caron, B ; Hébuterne, X...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1686-i1686 , 2024

Link: https://doi.org/10.1093/..

5

P733 Long-term effectiveness and acceptability of switching..:

Buisson, A ; Nachury, M ; Bazoge, M...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1374-i1374 , 2024

Link: https://doi.org/10.1093/..

6

DOP23 The role of histology for the prediction of clinical ..:

Reenaers Dr, C ; Enea, D ; Nachury, M...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i117-i117 , 2024

Link: https://doi.org/10.1093/..

7

P226 Disability in Crohn's Disease Patients at diagnosis: F..:

Revés, J ; Roager Madsen, G ; Burisch, J...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i563-i564 , 2024

Link: https://doi.org/10.1093/..

8

Infliximab is an effective option in patients with ulcerati..:

Hupé, M. ; Streichenberger, A. ; Wils, P....
Digestive and Liver Disease. , 2024

Link: https://doi.org/10.1016/..

9

P857 Effectiveness and safety of subcutaneous infliximab in..:

Andre, M ; Kirchgesner, J ; Laharie, D...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1587-i1587 , 2024

Link: https://doi.org/10.1093/..

10

P386 Persistence of bowel urgency despite clinical remissio..:

Buisson, A ; Amiot, A ; Nachury, M...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i812-i812 , 2024

Link: https://doi.org/10.1093/..

11

P404 Persistence of subcutaneous infliximab after switching..:

Mathieu, N ; Riviere, P ; Heluwaert, F...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i533-i534 , 2023

Link: https://doi.org/10.1093/..

12

Long‐term effectiveness and acceptability of switching from..:

Buisson, A. ; Nachury, M. ; Bazoge, M....
Alimentary Pharmacology & Therapeutics. 59 (2023) 4 - p. 526-534 , 2023

Link: https://doi.org/10.1111/..

13

P579 Real-world comparison of effectiveness between tofacit..:

Buisson, A ; Serrero, M ; Altwegg, R...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i707-i707 , 2023

Link: https://doi.org/10.1093/..

14

P638 Effectiveness and safety of risankizumab induction the..:

Fumery, M ; Defrance, A ; Roblin, X...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i770-i770 , 2023

Link: https://doi.org/10.1093/..

15

DOP89 Impact of biologics on the risk of early postoperativ..:

Fumery, M ; Nancey, S ; Nachury, M...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i166-i167 , 2023

Link: https://doi.org/10.1093/..